MGTX
MeiraGTx Holdings plc NASDAQ$9.70
Mkt Cap $897.8M
52w Low $4.55
70.5% of range
52w High $11.85
50d MA $8.48
200d MA $8.13
P/E (TTM)
-6.6x
EV/EBITDA
-6.2x
P/B
—
Debt/Equity
-15.3x
ROE
1971.4%
P/FCF
-12.7x
RSI (14)
—
ATR (14)
—
Beta
1.28
50d MA
$8.48
200d MA
$8.13
Avg Volume
662.9K
About
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Park…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.60 | 0.19 | +131.7% | 7.53 | +2.0% | +1.2% | +7.4% | +15.0% | +20.7% | +21.9% | +21.2% | — |
| Nov 13, 2025 | AMC | -0.50 | -0.62 | -24.0% | 8.26 | -1.8% | -0.8% | -4.6% | -6.2% | -8.2% | -10.0% | +7.7% | — |
| Aug 14, 2025 | AMC | -0.52 | -0.48 | +7.7% | 8.33 | -1.2% | -1.9% | -4.3% | -9.0% | -9.2% | -5.8% | -12.0% | — |
| May 13, 2025 | AMC | -0.38 | -0.51 | -34.2% | 5.15 | -1.0% | -9.9% | -2.1% | -3.1% | +0.0% | +6.8% | +28.0% | — |
| Mar 13, 2025 | AMC | -0.48 | -0.50 | -4.2% | 8.25 | +3.8% | -5.6% | -4.6% | -9.1% | -5.8% | -7.3% | -33.6% | — |
| Nov 13, 2024 | AMC | -0.47 | -0.54 | -14.9% | 7.04 | +1.7% | -5.7% | -8.0% | -13.5% | -15.1% | -17.3% | -13.1% | — |
| Aug 12, 2024 | AMC | -0.31 | -0.76 | -145.2% | 4.00 | -0.8% | +5.5% | +0.0% | +10.0% | +5.8% | +7.8% | +4.0% | — |
| May 9, 2024 | AMC | -0.32 | -0.77 | -140.6% | 5.10 | +1.4% | -0.6% | +0.8% | +2.5% | +8.4% | +11.4% | -5.9% | — |
| Mar 14, 2024 | AMC | -0.46 | -0.47 | -2.2% | 5.90 | -1.5% | +7.6% | +5.1% | +6.4% | +10.0% | +9.5% | -7.3% | — |
| Nov 14, 2023 | AMC | -0.63 | -0.74 | -17.5% | 4.84 | -1.4% | +2.3% | +5.6% | +16.5% | +16.9% | +13.2% | -3.5% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.17 | $10.58 | +4.0% | -1.4% | -8.4% | -9.2% | -10.2% | -10.7% |
| Apr 17 | RBC Capital | Maintains | Outperform → Outperform | — | $9.48 | $9.65 | +1.8% | +6.8% | +11.1% | +7.3% | +5.8% | -1.7% |
| Apr 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $8.66 | $8.77 | +1.3% | +5.0% | +6.0% | +9.9% | +9.8% | +8.4% |
| Mar 27 | Chardan Capital | Maintains | Buy → Buy | — | $7.53 | $7.68 | +2.0% | +1.2% | +7.4% | +15.0% | +20.7% | +21.9% |
| Mar 27 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.53 | $7.68 | +2.0% | +1.2% | +7.4% | +15.0% | +20.7% | +21.9% |
| Mar 27 | BofA Securities | Maintains | Buy → Buy | — | $7.53 | $7.68 | +2.0% | +1.2% | +7.4% | +15.0% | +20.7% | +21.9% |
| Nov 14 | RBC Capital | Maintains | Outperform → Outperform | — | $8.26 | $8.11 | -1.8% | -0.8% | -4.6% | -6.2% | -8.2% | -10.0% |
| Nov 14 | Chardan Capital | Maintains | Buy → Buy | — | $8.26 | $8.11 | -1.8% | -0.8% | -4.6% | -6.2% | -8.2% | -10.0% |
| Nov 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.55 | $8.70 | +1.8% | +4.1% | +1.3% | -3.4% | -4.2% | -7.8% |
| Nov 11 | Chardan Capital | Maintains | Buy → Buy | — | $8.55 | $8.70 | +1.8% | +4.1% | +1.3% | -3.4% | -4.2% | -7.8% |
Recent Filings
8-K · 1.01
!! High
MeiraGTx Holdings plc -- 8-K 1.01: Collaboration Agreement
MeiraGTx entered a $105 million collaboration agreement, likely expanding its gene therapy pipeline and providing significant funding for development programs.
Apr 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
MGTX's market research shows strong physician adoption potential for its product, with $3.2-3.7 billion peak revenue projections; this validates the commercial opportunity and could drive significant upside if clinical trials succeed and FDA approval follows.
Apr 16
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
MGTX completed a significant asset acquisition, which could accelerate growth, expand capabilities, or improve profitability—investors should monitor integration costs and synergy realization.
Apr 16
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Underwriting / Securities
MGTX secured underwriting services from BofA Securities for a likely upcoming capital raise, signaling management confidence in funding needs and potentially diluting current shareholders through new share issuance.
Apr 16
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
MGTX secured a strategic partnership with Hologen Limited that could expand its pipeline or commercial reach, making this worth monitoring for potential revenue catalysts or technology synergies.
Mar 26
Data updated apr 26, 2026 12:10pm
· Source: massive.com